

Clinical Trial Protocol

Iranian Registry of Clinical Trials

12 Jun 2026

Comparison of Dexmedetomidine , Lidocaine , Magnesium Sulfate and Remifentanil on stimulatory responses and cough suppression during tracheal tube removal among patients under general anesthesia

Protocol summary

Study aim

Comparison of Dexmedetomidine, Lidocaine, Magnesium Sulfate and Remifentanil to reduce stimulatory responses and cough suppression when tracheal tube removal

Design

The double blind randomized clinical trial, consisted of 120 patients who are randomly divided into 4 groups. The groups are parallel. The trial phase is 3.

Settings and conduct

The study population are patients undergoing general anesthesia, attending Valiasr hospital in Arak who are divided into 4 groups by simple randomization using envelopes. The study is double-blind in which outcome evaluator, data analyst and participant are kept blind.

Participants/Inclusion and exclusion criteria

Inclusion criteria: being at the age of 20 to 60 years old, ASA class 1 and 2, Malampati class I and II, Both gender, Not smoking, Not addicted, Lack of active airway infection or having a history of surgery and pathology of the chin and larynx, Body mass index less than 30, the duration of surgery is between 60 and 120 minutes
Exclusion criteria: Dissatisfaction of patients, lung and heart disease, not taking cough medicines, esophageal sphincter insufficiency and (lack of reflux), increased intracranial pressure and intraocular pressure

Intervention groups

Intervention group 1: infusion of 0.5 microgram/kilogram Dexmedetomidine slowly in 10 minutes. Intervention group 2: infusion of 1.5 milligram/kilogram Lidocaine slowly in 10 minutes. Intervention group 3: infusion of 1 microgram/kilogram Fentanyl slowly in 10 minutes. Intervention group 4: infusion of 30 milligram/kilogram magnesium sulphate slowly in 10 minutes.

Main outcome variables

Cough, laryngospasm

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20141209020258N149**

Registration date: **2020-09-23, 1399/07/02**

Registration timing: **registered_while_recruiting**

Last update: **2020-09-23, 1399/07/02**

Update count: **0**

Registration date

2020-09-23, 1399/07/02

Registrant information

Name

Fariba Farokhi

Name of organization / entity

Arak University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 86 3222 2003

Email address

f.farokhi@arakmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-06-09, 1399/03/20

Expected recruitment end date

2021-06-10, 1400/03/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of Dexmedetomidine , Lidocaine , Magnesium Sulfate and Remifentanil on stimulatory responses and cough suppression during tracheal tube removal among patients under general anesthesia

Public title

Comparison of Dexmedetomidine , Lidocaine , Magnesium Sulfate and Remifentanil on cough suppression during tracheal tube removal

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Age of 20 to 60 years ASA class 1 and 2 Malampati class I and II Body mass index less than 30 The duration of surgery is between 60 and 120 minutes

Exclusion criteria:

Dissatisfaction of patients lung and heart disease Take cough medicines Active airway infection or having a history of surgery and pathology of the chin and larynx Esophageal sphincter insufficiency and (lack of reflux) Increased intracranial pressure and intraocular pressure

Age

From **20 years** old to **60 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Outcome assessor
- Data analyser

Sample size

Target sample size: **120**

Randomization (investigator's opinion)

Randomized

Randomization description

Simple individual randomization with envelopes into 4 groups of A; B; C and D. In this method, we write some letters on the cards as intervention groups and the same numbers on the cards for the control group, then the cards are mixed. One card is taken out and its allocation is registered and the card is returned to the other cards after leaving. Then the cards are mixed again and another card is picked up. This process continues to reach a random sequence according to sample size.

Blinding (investigator's opinion)

Double blinded

Blinding description

This study is double blind. Outcome evaluator and analyzer and participant are blind. Outcome evaluator and analyzer and participant don't aware of grouping.

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Arak University of Medical Sciences

Street address

Ethics committee, Research center, Payambar Azam complex, Basij square ,Sardasht, Arak

City

Arak

Province

Markazi

Postal code

3848176941

Approval date

2020-06-07, 1399/03/18

Ethics committee reference number

IR.ARAKMU.REC.1399.093

Health conditions studied

1

Description of health condition studied

General anesthesia

ICD-10 code

T88.4

ICD-10 code description

Failed or difficult intubation

Primary outcomes

1

Description

Cough

Timepoint

At the beginning of the study and then every 5 minutes to 40 minutes

Method of measurement

Observation

2

Description

Laryngospasm

Timepoint

At the beginning of the study and then every 5 minutes to 40 minutes

Method of measurement

Observation

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group 1: We infuse 0.5 microgram/kilogram Dexmedetomidine (Exir company, Tehran, Iran) slowly during 10 minutes.

Category

Treatment - Drugs

2

Description

Intervention group 2: We infuse 1.5 milligram/kilogram Lidocaine (Caspian company, Rasht; Iran) slowly during 10 minutes.

Category

Treatment - Drugs

3

Description

Intervention group 3: We infuse 1 micro gram in kilogram Fentanyl (Normon,S.A company; Madrid; Spain) slowly in 10 minutes.

Category

Treatment - Drugs

4

Description

Intervention group 4: We infuse 30 milligram/kilogram magnesium sulphate 20% (Shahid Ghazi company, Tabriz, Iran) slowly during 10 minutes.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Valiasr hospital

Full name of responsible person

Dr Hesamodin Modir

Street address

Valiasr hospital, Valiasr square

City

Arak

Province

Markazi

Postal code

3848176941

Phone

+98 86 3222 2003

Email

modir.he@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr Alireza Kamali

Street address

Research Center, Payambar Azam Complex, Basij square, Sardasht, Arak

City

Arak

Province

Markazi

Postal code

3848176941

Phone

+98 86 3222 2003

Fax

+98 86 3222 2003

Email

alikalaliir@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Arak University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Dr Esmaeel Moshiri

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Valiasr hospital; Valiasr square; Shahid Shirodi street

City

Arak

Province

Markazi

Postal code
3814957558
Phone
+98 86 3222 2003
Fax
+98 86 3222 2003
Email
modir.he@gmail.com
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Dr Hesamedin Modir
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Valiasr Hospital, Valiasr square, Shahid Shirodi street
City
Arak
Province
Markazi
Postal code
3814957558
Phone
+98 86 3222 2003
Email
modir.he@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Ehsan Jafarzadeh
Position
Medicine student
Latest degree
Medical doctor
Other areas of specialty/work
General Practitioner
Street address

Payambar Azam complex, Basij square; Sardasht
City
Arak
Province
Markazi
Postal code
3814957558
Phone
+98 86 3222 2003
Fax
+98 86 3222 2003
Email
modir.he@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

Age, sex, information on cough and laryngospasm and any other information that is collected and analyzed

When the data will become available and for how long

After finishing the work

To whom data/document is available

Researchers

Under which criteria data/document could be used

Research

From where data/document is obtainable

Dr. Hesamodin Modir

What processes are involved for a request to access data/document

Correspondence via email modir.he@gmail.com

Comments